Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.70 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.70 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.65 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.61 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.47 |
| ▸ | HRH1 | P35367 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22762150 | 0.88 | TDP1 (0.61) | TDP1L3MBTL1SIGMAR1CHRM2CYP2A6 | |
| SCHEMBL16606311 | 0.86 | CYP1A2 (0.63) | TDP1L3MBTL1CHRM2CYP2A6CYP1A2 | |
| SCHEMBL2188249 | 0.85 | CHRM2 (0.78) | TDP1L3MBTL1CHRM2CYP1A2CYP2D6 | |
| SCHEMBL6159311 | 0.84 | SIGMAR1 (0.71) | TDP1L3MBTL1SIGMAR1CHRM2 | |
| SCHEMBL11083068 | 0.84 | CHRM2 (0.81) | TDP1L3MBTL1CHRM2CYP1A2CYP2D6 | |
| SCHEMBL19509215 | 0.84 | CHRM2 (0.81) | TDP1L3MBTL1CHRM2CYP1A2CYP2D6 | |
| SCHEMBL10556589 | 0.84 | CHRM2 (0.81) | TDP1L3MBTL1CHRM2CYP1A2CYP2D6 | |
| SCHEMBL10282657 | 0.83 | TDP1 (0.58) | TDP1L3MBTL1CHRM2CYP2A6CYP1A2 | |
| SCHEMBL16606319 | 0.83 | CHRM2 (0.68) | TDP1L3MBTL1SIGMAR1CHRM2CYP2A6 | |
| SCHEMBL135032 | 0.83 | TDP1 (1.00) | TDP1L3MBTL1CYP2A6TRPV1CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110200549-A1 | Organic Compounds Suitable For Modulating Fragrance Compositions | GIVAUDAN SA (CH) | 2011-08-18 | — | — | US | disclosed |
| EP-2342180-A2 | ORGANIC COMPOUNDS SUITABLE FOR MODULATING FRAGRANCE COMPOSITIONS | Givaudan SA (CH) | 2011-07-13 | — | — | EP | disclosed |
| WO-2010037244-A2 | ORGANIC COMPOUNDS | GIVAUDAN SA (CH) | 2010-04-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110200549-A1 | Organic Compounds Suitable For Modulating Fragrance Compositions | CYP2A6, CYP2B6, CYP2A13 | TDP1 3040/4885L3MBTL1 4165/4885SIGMAR1 1400/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.